Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 14.3%Low 3 · 42.9%Moderate 3 · 42.9%High 0 · 0%

Budesonide vs mesalamine

Endoscopic remission · Adult patients with active ulcerative colitis

Budesonide showed no clear difference in endoscopic remission (EI ≤ 1) compared with mesalamine (moderate certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 0.78 [0.58, 1.04]
1 study · 343 participants
Moderate

Budesonide 10 mg vs prednisolone

Endoscopic remission · Adult patients with active ulcerative colitis

It is very uncertain whether budesonide 10 mg changes endoscopic remission compared with prednisolone 40 mg (very low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 0.75 [0.23, 2.42]
1 study · 72 participants
Very low

Budesonide vs mesalamine

Remission (combined clinical and endoscopic remission) · Adult patients with active ulcerative colitis

Budesonide showed no clear difference in remission (combined clinical and endoscopic remission) compared with mesalamine (low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.48 [0.81, 2.71]
1 study · 247 participants
Low

Budesonide MMX® 9 mg vs placebo

Endoscopic remission · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg probably leads to higher endoscopic remission compared with placebo (moderate certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.56 [1.13, 2.16]
2 studies · 695 participants
Moderate

Budesonide MMX® 6 mg vs placebo

Remission (combined clinical and endoscopic remission) · Adult patients with active ulcerative colitis

Budesonide MMX® 6 mg showed no clear difference in remission (combined clinical and endoscopic remission compared with placebo (low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.8 [0.94, 3.42]
2 studies · 440 participants
Low

Budesonide MMX® 9 mg vs placebo

Remission (combined clinical and endoscopic remission) · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg probably leads to higher remission (combined clinical and endoscopic remission) compared with placebo (moderate certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 2.25 [1.5, 3.39]
3 studies · 900 participants
Moderate

Budesonide MMX® 9 mg vs Entocort EC 9mg

Remission (combined clinical and endoscopic remission) · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg showed no clear difference in remission (combined clinical and endoscopic remission) compared with entocort EC 9mg (low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.38 [0.72, 2.65]
1 study · 212 participants
Low